Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levallorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.86 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.69 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.69 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.69 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.69 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levallorphan SCHEMBL20505815 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12232843 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL29368769 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL209271 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12233279 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL16311899 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Dextallorphan SCHEMBL29438705 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL678413 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL8459964 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL5675160 | 0.97 | OPRM1 (0.94) | OPRM1OPRK1KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8101 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665315-A1 | METHODS OF PREPARATION OF ZINGERONE, COMPOSITIONS COMPRISING ZINGERONE, AND USES THEREFOR | Evithe Limited (NZ) | 2025-12-24 | — | — | EP | claimed |
| US-20250381148-A1 | PREPARATION OF ABUSE-DETERRENT PHARMACEUTICAL FORMULATIONS USING VAPOR PHASE DEPOSITION | APPLIED MATERIALS INC (US) | 2025-12-18 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250246289-A1 | DYNAMICALLY TARGETING SUBSTANCE USE DISORDERS AND CONDITIONS VIA PERSONALIZED DIGITAL THERAPEUTICS | Click Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-4434168-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-02-28 | — | — | US | claimed |
| EP-0078434-A1 | Pharmaceutical and dietary compositions | EFAMOL LIMITED (GB) | 1983-05-11 | — | — | EP | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| EP-0077723-A1 | Pharmaceutical composition with an antagonist peripheric action of the narcotics | SANOFI S.A. (FR) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| EP-0037175-A1 | Pharmaceutical compositions | EFAMOL LIMITED (GB) | 1981-10-07 | — | — | EP | claimed |
| EP-0035856-A2 | Pharmaceutical and dietary compositions | EFAMOL LIMITED (GB) | 1981-09-16 | — | — | EP | claimed |
| US-4267182-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1981-05-12 | — | — | US | claimed |
| EP-0019423-A1 | Pharmaceutical and dietary composition comprising gamma-linolenic acids | EFAMOL LIMITED (GB) | 1980-11-26 | — | — | EP | claimed |